Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic TherapiesCompleted
NCT06616415Phase 4Updated May 27, 2026
Sponsor: Sanofi
Chronic Graft Versus Host Disease
China
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema TrialCompleted
NCT05590585Phase 4Updated May 27, 2026
Sponsor: Regeneron Pharmaceuticals
Moderate-to-Severe Atopic Dermatitis · Atopic Eczema
United States
Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma ExacerbationNot Yet Recruiting
NCT07396987NAUpdated May 26, 2026
Sponsor: Juan Carlos Cardet
Asthma Attack · Asthma Control · Asthma Exacerbations · Asthma
Follow-up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment.Recruiting
NCT07606508N/AUpdated May 26, 2026
Sponsor: University Hospital, Lille
Cutaneous Squamous Cell Carcinoma (CSCC)
France
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled AsthmaActive Not Recruiting
NCT06572228Phase 4Updated May 22, 2026
Sponsor: Regeneron Pharmaceuticals
Asthma
United States, Canada, Denmark, Germany, Poland +1 more
Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of AgeRecruiting
NCT07348692Phase 3Updated May 22, 2026
Sponsor: Sanofi
Pneumococcal Immunization · Healthy Volunteers
United States, Honduras, Puerto Rico
A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)Enrolling By Invitation
NCT07222189Phase 2Updated May 22, 2026
Sponsor: Sanofi
Colitis Ulcerative · Crohn's Disease
Bulgaria, Chile
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)Recruiting
NCT02991469Phase 2Updated May 22, 2026
Sponsor: Sanofi
Juvenile Idiopathic Arthritis
Argentina, Canada, Finland, France, Germany +7 more
A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic DiseasesRecruiting
NCT06647069Phase 1Updated May 22, 2026
Sponsor: Sanofi
Systemic Lupus Erythematosus (SLE) · Rheumatoid Arthritis (RA)
Australia, Bosnia and Herzegovina, New Zealand, South Africa
Cognition and MRI Markers in MS Patients With Aubagio® TreatmentCompleted
NCT03768648NAUpdated May 20, 2026
Sponsor: University Hospital, Bordeaux
Multiple Sclerosis, Relapsing-Remitting
France
A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older AdultsActive Not Recruiting
NCT06556147Phase 1Updated May 20, 2026
Sponsor: Sanofi
Healthy Volunteers
Australia
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical StudyActive Not Recruiting
NCT06033833Phase 2Updated May 20, 2026
Sponsor: Sanofi
Asthma
United States, Argentina, Brazil, Canada, Chile +9 more
French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)Recruiting
NCT06837454N/AUpdated May 20, 2026
Sponsor: Sanofi
Atopic Dermatitis
France
Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older AdultsActive Not Recruiting
NCT07295028Phase 1Updated May 20, 2026
Sponsor: Sanofi
Lower Respiratory Tract Disease · Healthy Participants
Australia
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple MyelomaNot Yet Recruiting
NCT07600151Phase 1, Phase 2Updated May 20, 2026
Sponsor: Universitätsklinikum Hamburg-Eppendorf
Myeloma Multiple · Myeloma
Germany
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsActive Not Recruiting
NCT06834347Phase 3Updated May 20, 2026
Sponsor: Sanofi
Chronic Rhinosinusitis With Nasal Polyps
United States, Argentina, Austria, Brazil, Canada +16 more
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung CancerCompleted
NCT03409614Phase 3Updated May 18, 2026
Sponsor: Regeneron Pharmaceuticals
Non-small Cell Lung Cancer
United States, Austria, China, France, Georgia +13 more
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPDActive Not Recruiting
NCT06208306Phase 3Updated May 18, 2026
Sponsor: Sanofi
Chronic Obstructive Pulmonary Disease
United States, Argentina, Brazil, Bulgaria, Canada +27 more
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer PatientsTerminated
NCT04154956Phase 3Updated May 18, 2026
Sponsor: Sanofi
Non-small Cell Lung Cancer Metastatic
United States, Argentina, Australia, Belgium, Brazil +21 more
Pertussis Vaccination Among HIV-infected and HIV-uninfected Pregnant WomenCompleted
NCT05264662Phase 4Updated May 15, 2026
Sponsor: Farzanah Laher
dTap Vaccine
South Africa
Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in TaiwanActive Not Recruiting
NCT06052800N/AUpdated May 15, 2026
Sponsor: Sanofi
Fabry Disease
Taiwan
Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic DermatitisCompleted
NCT06099704N/AUpdated May 15, 2026
Sponsor: Sanofi
Moderate to Severe Atopic Dermatitis
Canada
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple SclerosisActive Not Recruiting
NCT06141486Phase 3Updated May 14, 2026
Sponsor: Sanofi
Multiple Sclerosis
United States, Argentina, Australia, Belgium, Brazil +22 more
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple MyelomaRecruiting
NCT07479979Phase 1, Phase 2Updated May 14, 2026
Sponsor: Natalie Callander
Relapse Multiple Myeloma · Refractory Multiple Myeloma
United States
This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring HospitalizationNot Yet Recruiting
NCT07587658Phase 4Updated May 14, 2026
Sponsor: Regeneron Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)

Previous page Next page